Business
Update on AI/ML-Ab™ antibody discovery service
Update on AI/ML-Ab™ antibody discovery service.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n \n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nUpdate on AI/ML-AbTM antibody discovery service\nNew commerical service from OptiMAL® programme\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces an update on the Company's AI/ML-AbTM (pronounced AIM-Lab) service offering.\n \nOn 19 May 2023, the Company announced that it had signed memoranda of understanding with two AI/ML (artificial intelligence and machine learning) companies. The Company is pleased to announce that that is has now signed an agreement (the \"Agreement\") with the first of the companies, a leading US-based AI/ML business, to support Fusion's new AI/ML-AbTM service offering. Pursuant to the Agreement, it is envisaged that both parties will co-market the combined service offerings covering both the in silico AI/ML design of antibodies and their production and evaluation in vitro.\n \nEach party to the Agreement will be entitled to a fee for any new business introduced to the other. Both parties have already combined to begin commercialisation of the offering and are processing multiple leads derived by both entities.\n \nAI/ML-AbTM combines the latest AI enabled technology for in silico design of antibody sequences with Fusion's established core expertise in antibody expression and evaluation. Furthermore, AI/ML-AbTM can also employ Fusion's recently announced proprietary Mammalian Display platform to enable screening of focused libraries derived from AI/ML design outputs. By combining the two approaches, clients will be able to screen thousands or even millions of sequences rather than the tens or hundreds to which such projects tend to be restricted. Increasing the number of sequences to be screened by a factor of 1,000 or more significantly enhances the prospects of finding the most appropriate leads from AI/ML discovery projects, not only de-risking this novel cutting-edge approach to antibody discovery but also achieving this at a significantly lower cost per sequence.\n \nFusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic ta...